Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer

Stopped early

Conditions studied: Neoplasms, Breast

In brief

This study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.

Key facts

Study ID

NCT01476111

Run by

GlaxoSmithKline

People needed

117

Starts

2011-12-01

Expected to finish

2014-07-01

Last updated by the study team

2015-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patient has 18 years of age or older at the time of consent.
• The patient has provided pre-treatment tumor samples for WT1 expression screening and gene expression profiling in the context of the NCT01220128 study.
• The patient has a histologically or cytologically confirmed primary invasive breast cancer.
• The patient has provided written informed consent before any new information or new material is provided to the Sponsor.
• The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.
• The patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer.

You may not qualify if…

• Not applicable.

Where it is running

• GSK Investigational Site — Newark, Delaware, United States
• GSK Investigational Site — Plantation, Florida, United States
• GSK Investigational Site — Charleston, South Carolina, United States
• GSK Investigational Site — Amarillo, Texas, United States
• GSK Investigational Site — Brussels, Belgium
• GSK Investigational Site — Namur, Belgium
• GSK Investigational Site — Tübingen, Baden-Wurttemberg, Germany
• GSK Investigational Site — Erlangen, Bavaria, Germany
• GSK Investigational Site — Frankfurt am Main, Hesse, Germany
• GSK Investigational Site — Rostock, Mecklenburg-Vorpommern, Germany
• GSK Investigational Site — Dortmund, North Rhine-Westphalia, Germany
• GSK Investigational Site — Essen, North Rhine-Westphalia, Germany
• GSK Investigational Site — Homburg, Saarland, Germany
• GSK Investigational Site — Chemnitz, Saxony, Germany
• GSK Investigational Site — Kiel, Schleswig-Holstein, Germany
• GSK Investigational Site — Naples, Campania, Italy
• GSK Investigational Site — Aviano (PN), Friuli Venezia Giulia, Italy
• GSK Investigational Site — Rome, Lazio, Italy
• GSK Investigational Site — Milan, Lombardy, Italy
• GSK Investigational Site — Pavia, Lombardy, Italy
• GSK Investigational Site — Turin, Piedmont, Italy
• GSK Investigational Site — Ryazan, Russia
• GSK Investigational Site — Saint Petersburg, Russia
• GSK Investigational Site — Saint Petersburg, Russia
• GSK Investigational Site — Bournemouth, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.